The United States President Donald Trump has introduced a new set of trade measures targeting pharmaceutical imports, with tariffs of up to 100 percent on certain branded pharmaceutical imports and changes to steel, aluminum, and copper duties. The measures are intended to force foreign drugmakers to cut prices and increase manufacturing in the United States. Companies that do not comply with pricing demands will face a 20 percent tariff, while companies that do neither will be subject to a 100 percent duty. The tariffs will not apply uniformly across all countries, with imports from the European Union, Japan, South Korea, and Switzerland facing a capped rate of 15 percent under existing trade agreements. Alongside the pharmaceutical measures, Trump signed a proclamation revising tariffs on metals, which will be reduced to 25 percent and remove a 50 percent duty on core imports of these metals. The changes to metals tariffs are set to take effect on April 6. However, business groups warn that these measures could increase costs and strain industries already facing high input costs and challenges.